# US 2008/0075724 A1 · Molecules designated B7L-1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0075724 A1
- Document ID: US20080075724A1
- Status: Published application
- Kind: A1
- Application number: 11/981,954
- Filed: 2007-10-31
- Published: 2008-03-27
- Earliest claimed: 1998-08-07
- Assignees: Immunex Corporation
- Inventors: Peter Baum
- Web page: https://patentgrep.com/patent/US20080075724A1

## CPC

- C07K 14/70532: {B7 molecules, e.g. CD80, CD86}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C12N 2799/027: where the vector is derived from a retrovirus
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention is directed to B7L-1 as a purified and isolated protein, the DNA encoding the B7L-1, host cells transfected with cDNAs encoding B7L-1 and processes for preparing B7L-1 polypeptides.

## Claims

### Claim 1

An isolated DNA sequence encoding a polypeptide that is at least 80% identical to the sequence of amino acid residues selected from the group consisting of amino acids I-432 of SEQ ID NO:2, amino acids 1-398 of SEQ ID NO:4, and amino acids 1-398 of SEQ ID NO:6, the polypeptide being capable of binding to a LDCAM polypeptide.

### Claim 2

An isolated DNA sequence encoding a polypeptide having an amino acid sequence selected from the group SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6.

### Claim 3

An isolated DNA encoding a soluble polypeptide wherein said soluble polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence selected from the group consisting of:
a) amino acids x1 to 364 of SEQ ID NO:2, wherein x1 is amino acid 1 or 21;
b) amino acids x1′ to 330 of SEQ ID NO:4, where x1′ is amino acid 1 or 21;
c) amino acids y1 to 330 of SEQ ID NO:6, wherein y1 is amino acid 1 or 21; and
d) a fragment of the sequences of a) b) or c),
wherein the soluble polypeptide is capable of binding to a LDCAM polypeptide.

### Claim 4

An isolated DNA encoding a soluble polypeptide wherein said soluble polypeptide comprises an amino acid sequence selected from the group consisting of:
a) amino acids x1 to 364 of SEQ ID NO:2, wherein x1 is amino acid 1 or 21;
b) amino acids x1′ to 330 of SEQ ID NO:4, where x1′ is amino acid 1 or 21;
c) amino acids y1 to 330 of SEQ ID NO:6, wherein y1 is amino acid 1 or 21; and
d) a fragment of the sequences of a) b) or c),

### Claim 5

DNA selected from the group consisting of:
a) nucleic acids x1 to 1452 of SEQ ID NO:1, wherein x1 is nucleic acid 157 or 217;
b) nucleic acids x1′ to 1206 of SEQ ID NO:3, wherein x1′ is nucleic acid 13 or 73;
c) nucleic acids y1 to 1350 of SEQ ID NO:5, wherein y1 is nucleic acid 157 or 217;
d) DNA sequences that hybridize under moderately stringent conditions to the DNA of a) b) or c); and which DNA sequences encode a polypeptide that binds itself; and
e) DNA complementary to the DNA of a), b) c) and d).
f) DNA sequences that, due to the degeneracy of the genetic code, encode B7L-1 polypeptide having the amino acid sequence of the polypeptide encoded by the DNA sequences of a), b), c) d) or e).

### Claim 6

A polypeptide encoded by DNA selected from the group consisting of:
a) nucleic acids x1 to 1452 of SEQ ID NO:1, wherein x1 is nucleic acid 157 or 217;
b) nucleic acids x1′ to 1206 of SEQ ID NO:3, wherein x1′ is nucleic acid 13 or 73;
c) nucleic acids y1 to 1350 of SEQ ID NO:5, wherein y1 is nucleic acid 157 or 217;
d) DNA sequences that hybridize under moderately stringent conditions to the DNA of a) b) or c); and which DNA sequences encode a polypeptide that binds itself; and
e) DNA complementary to the DNA of a), b) c) and d).
f) DNA sequences that, due to the degeneracy of the genetic code, encode B7L-1 polypeptide having the amino acid sequence of the polypeptide encoded by the DNA sequences of a), b), c) d) or e).

### Claim 7

A polypeptide comprising an amino acid sequence that is at least 80% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6, the polypeptide being capable of binding to a LDCAM polypeptide.

### Claim 8

A soluble polypeptide comprising an amino acid sequence selected from the group consisting of:
a) amino acids x1 to 364 of SEQ ID NO:2, wherein x1 is amino acid 1 or 21;
b) amino acids x1′ to 330 of SEQ ID NO:4, where x1′ is amino acid 1 or 21;
c) amino acids y1 to 330 of SEQ ID NO:6, wherein y1 is amino acid 1 or 21; and
d) a fragment of the sequences of a) b) or c),
wherein the fragment is capable of binding to a LDCAM polypeptide.

### Claim 9

A soluble polypeptide comprising an amino acid sequence that is at least 90% identical to an amino acids sequence selected from the group consisting of:
a) amino acids x1 to 364 of SEQ ID NO:2, wherein x1 is amino acid 1 or 21;
b) amino acids x1′ to 330 of SEQ ID NO:4, where x1′ is amino acid 1 or 21;
c) amino acids y1 to 330 of SEQ ID NO:6, wherein y1 is amino acid 1 or 21; and
d) a fragment of the sequences of a) b) or c)
wherein the soluble polypeptide is capable of binding to a LDCAM polypeptide.

### Claim 10

A fusion protein comprising an amino acid selected from the group consisting of:
a) amino acids x1 to 364 of SEQ ID NO:2, wherein x1 is amino acid 1 or 21;
b) amino acids x1′ to 330 of SEQ ID NO:4, where x1′ is amino acid 1 or 21;
c) amino acids y1 to 330 of SEQ ID NO:6, wherein y1 is amino acid 1 or 21; and
d) a fragment of the sequences of a) b) or c),
wherein the fragment is capable of binding to a LDCAM polypeptide

### Claim 11 (depends on 1)

A recombinant expression vector comprising DNA of claim 1.

### Claim 12 (depends on 11)

A process for preparing a polypeptide, the process comprising culturing a host cell transformed with an expression vector of claim 11 under conditions that promote expression of the polypeptide, and recovering the polypeptide.

### Claim 13 (depends on 7)

A composition comprising a suitable carrier and a polypeptide of claim 7.

### Claim 14 (depends on 3)

A recombinant expression vector comprising DNA of claim 3.

### Claim 15 (depends on 14)

A process for preparing a polypeptide, the process comprising culturing a host cell transformed with an expression vector of claim 14 under conditions that promote expression of the polypeptide, and recovering the polypeptide.

### Claim 16

An isolated antibody that binds B7L-1.

### Claim 17 (depends on 16)

The antibody of claim 16, wherein said B7L-1 is soluble.

### Claim 18

An isolated antibody that binds a polypeptide having an amino acid sequence consisting of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO:6.

### Claim 19

A method of treating a subject having a disease mediated by B7L-1 comprising administering to said subject an antibody that binds B7L-1.

### Claim 20

A method of treating a subject having a disease mediated by B7L-1 comprising administering to said subject a polypeptide comprising an extracellular domain of B7L-1.

### Claim 21

A method of depleting or eliminating myeloid dendritic cells comprising contacting said myeloid dendritic cells with an antibody that binds B7L-1.
